First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma: results of the B-R-ENDA trial
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and effica...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
Dec 1, 2022
|
| In: |
HemaSphere
Year: 2022, Jahrgang: 6, Heft: 12, Pages: 1-10 |
| ISSN: | 2572-9241 |
| DOI: | 10.1097/HS9.0000000000000808 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/HS9.0000000000000808 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/hemasphere/Fulltext/2022/12000/First_line_Treatment_With_Bendamustine_and.12.aspx 
|
| Verfasserangaben: | Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1837269327 | ||
| 003 | DE-627 | ||
| 005 | 20231109142210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230222s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HS9.0000000000000808 |2 doi | |
| 035 | |a (DE-627)1837269327 | ||
| 035 | |a (DE-599)KXP1837269327 | ||
| 035 | |a (OCoLC)1389534068 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Braulke, Friederike |d 1979- |e VerfasserIn |0 (DE-588)131921509 |0 (DE-627)516081012 |0 (DE-576)267176988 |4 aut | |
| 245 | 1 | 0 | |a First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma |b results of the B-R-ENDA trial |c Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper |
| 264 | 1 | |c Dec 1, 2022 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.11.2023 | ||
| 520 | |a The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option. | ||
| 700 | 1 | |a Zettl, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ziepert, Marita |e VerfasserIn |4 aut | |
| 700 | 1 | |a Viardot, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kahl, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Prange-Krex, Gabriele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Korfel, Agnieszka |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreyling, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bott, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wedding, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reichert, Dietmar |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Wit, Maike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hartmann, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Poeschel, Viola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Altmann, Bettina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trümper, Lorenz |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d Hoboken : John Wiley & Sons Ltd., 2017 |g 6(2022), 12 vom: Dez., Artikel-ID e808, Seite 1-10 |h Online-Ressource |w (DE-627)1015324924 |w (DE-600)2922183-3 |w (DE-576)500571066 |x 2572-9241 |7 nnas |a First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma results of the B-R-ENDA trial |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:12 |g month:12 |g elocationid:e808 |g pages:1-10 |g extent:10 |a First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma results of the B-R-ENDA trial |
| 856 | 4 | 0 | |u https://doi.org/10.1097/HS9.0000000000000808 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/hemasphere/Fulltext/2022/12000/First_line_Treatment_With_Bendamustine_and.12.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230222 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |d 50000 |e 910000PW1050736516 |e 910100PW1050736516 |e 50000PW1050736516 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 16 | ||
| 999 | |a KXP-PPN1837269327 |e 4275485572 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 09.11.2023"],"language":["eng"],"recId":"1837269327","person":[{"given":"Friederike","family":"Braulke","role":"aut","roleDisplay":"VerfasserIn","display":"Braulke, Friederike"},{"given":"Florian","family":"Zettl","role":"aut","roleDisplay":"VerfasserIn","display":"Zettl, Florian"},{"family":"Ziepert","given":"Marita","display":"Ziepert, Marita","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Viardot, Andreas","roleDisplay":"VerfasserIn","role":"aut","family":"Viardot","given":"Andreas"},{"roleDisplay":"VerfasserIn","display":"Kahl, Christoph","role":"aut","family":"Kahl","given":"Christoph"},{"display":"Prange-Krex, Gabriele","roleDisplay":"VerfasserIn","role":"aut","family":"Prange-Krex","given":"Gabriele"},{"roleDisplay":"VerfasserIn","display":"Korfel, Agnieszka","role":"aut","family":"Korfel","given":"Agnieszka"},{"family":"Dreyling","given":"Martin","display":"Dreyling, Martin","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Bott, Alexander","roleDisplay":"VerfasserIn","given":"Alexander","family":"Bott"},{"family":"Wedding","given":"Ulrich","display":"Wedding, Ulrich","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Reichert, Dietmar","roleDisplay":"VerfasserIn","role":"aut","family":"Reichert","given":"Dietmar"},{"display":"de Wit, Maike","roleDisplay":"VerfasserIn","role":"aut","family":"de Wit","given":"Maike"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hartmann, Frank","given":"Frank","family":"Hartmann"},{"role":"aut","display":"Poeschel, Viola","roleDisplay":"VerfasserIn","given":"Viola","family":"Poeschel"},{"roleDisplay":"VerfasserIn","display":"Schmitz, Norbert","role":"aut","family":"Schmitz","given":"Norbert"},{"family":"Witzens-Harig","given":"Mathias","display":"Witzens-Harig, Mathias","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Klapper, Wolfram","given":"Wolfram","family":"Klapper"},{"roleDisplay":"VerfasserIn","display":"Rosenwald, Andreas","role":"aut","family":"Rosenwald","given":"Andreas"},{"given":"Gerald","family":"Wulf","role":"aut","roleDisplay":"VerfasserIn","display":"Wulf, Gerald"},{"roleDisplay":"VerfasserIn","display":"Altmann, Bettina","role":"aut","family":"Altmann","given":"Bettina"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Trümper, Lorenz","given":"Lorenz","family":"Trümper"}],"title":[{"title_sort":"First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma","subtitle":"results of the B-R-ENDA trial","title":"First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma"}],"physDesc":[{"noteIll":"Diagramme","extent":"10 S."}],"relHost":[{"origin":[{"publisherPlace":"Hoboken ; [Philadelphia, Pennsylvania]","dateIssuedDisp":"2024-","publisher":"John Wiley & Sons Ltd. ; Wolters Kluwer Health","dateIssuedKey":"2024"}],"id":{"eki":["1015324924"],"zdb":["2922183-3"],"issn":["2572-9241"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"HemaSphere","title":"HemaSphere","subtitle":"open access journal of the European Hematology Association"}],"note":["Gesehen am 18.01.2024"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma results of the B-R-ENDA trialHemaSphere","recId":"1015324924","language":["eng"],"corporate":[{"role":"isb","display":"European Hematology Association","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["Volume 1, issue 1 (December 2017)-"],"part":{"extent":"10","text":"6(2022), 12 vom: Dez., Artikel-ID e808, Seite 1-10","volume":"6","issue":"12","pages":"1-10","year":"2022"}}],"name":{"displayForm":["Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"Dec 1, 2022"}],"id":{"doi":["10.1097/HS9.0000000000000808"],"eki":["1837269327"]}} | ||
| SRT | |a BRAULKEFRIFIRSTLINET1202 | ||